Italian Government Defies Court Ruling, Lists CBD as Narcotic

Jul.15.2024
Italian Government Defies Court Ruling, Lists CBD as Narcotic
Italy defies EU law, listing CBD as narcotic. Italy's move sparks backlash from hemp industry, threatens 10,000 jobs.

According to a report from Hemptoday on July 12, the Italian government has ignored a ruling from a regional administrative court and violated EU law by placing CBD on the country's list of narcotic drugs.


The Italian Ministry of Health stated that this regulation complies with Italian Presidential Decree 309/1990, which forms the cornerstone of Italy's drug legislation. However, this contradicts a ruling from a regional court last year, which was based on legally binding judgments within the European Union.


This is the latest move by the Italian government against CBD. In October 2020, the Ministry of Health classified CBD as a narcotic drug for the first time and banned it from the market, but soon after revoked the order.


In another attempt in early 2022, the national-regional conference updated the language in the 2018 regulation, officially categorizing marijuana as a medicinal plant.


In that scenario, four major cannabis associations filed a lawsuit and the Lazio Regional Administrative Court overturned the regulation a year later, ruling that it violated European law. The European Commission announced in 2020 that CBD is not a narcotic drug and can be legally traded between member states. This decision was based on a landmark ruling by the European Court of Justice the same year.


The Italian Farmers' Association, Cia-Agricoltori Italiani, criticized the government in a statement for not consulting producers before listing CBD as a dangerous drug, stating that this move "has insulted farmers who have invested money and work in the industrial hemp supply chain in recent years".


The farmer's organization stated that


This is not only a controversial measure from legal, health, and scientific perspectives, but also an intervention that could potentially make the already heavily strained supply chain even more complicated.


According to CIA-Agricoltori Italiani, these prejudices are further reflected in a current amendment in the Italian parliament, which aims to ban CBD and all other products derived from hemp flowers.


The group's chairman, Cristiano Fini, stated that


We are facing potential ideological interference that could paralyze a high-value-added supply chain that attracts young people. This supply chain has huge production potential in cosmetics, herbs, green construction, floriculture, and textiles, with an annual turnover of 500 million euros and providing over 10,000 jobs.


Currently circulating in parliament is a proposed amendment that would completely ban cannabis flowers, affecting various aspects of production and trade. The leading cannabis industry organization, Federcanapa, has expressed that the provisions would effectively shut down the sub-industry of cannabis extracts, affecting the use of CBD and other non-psychoactive cannabinoids in herbal remedies, cosmetics, and dietary supplements.


Some lawmakers and other experts have stated that the amendment would result in the closure of 3,000 businesses and the unemployment of 15,000 workers.


Finney stated that Cia-Agricoltori Italiani has invited government representatives to discuss with CBD operators.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Special report|Indonesia's Vape Industry Has 200 Manufacturers and $1.7 Billion in Investment. Could a Regulatory Divide Derail Its Rise as the World's No. 2 Manufacturing Hub After Shenzhen?
Special report|Indonesia's Vape Industry Has 200 Manufacturers and $1.7 Billion in Investment. Could a Regulatory Divide Derail Its Rise as the World's No. 2 Manufacturing Hub After Shenzhen?
Indonesia's Ministry of Industry said at a November 3, 2026, policy forum that the country has about 200 electronic cigarette companies, Rp31 trillion (approximately $1.71 billion) in cumulative industry investment and around 100,000 jobs across the supply chain. The National Narcotics Agency is seeking a comprehensive ban on vape use and circulation, while the industry ministry favors tighter import, product-standard and distribution controls. Indonesia exported approximately $518 million in vaping products in 2025, and Chinese manufacturers including Smoore, GEEKVAPE and Jinjia Group have established local operations. An international logistics specialist interviewed by 2Firsts said more Chinese vape companies began production in Indonesia from the second half of 2025, accompanied by increased shipments of manufacturing equipment and investment in logistics facilities. The regulatory debate comes as Indonesia expands its role in international vaping manufacturing.
Special Report
Nov.05
UK ONS Data: Vaping Rate Among Women Aged 25–34 Reaches 18.3%, Compared With 14.4% for Men
UK ONS Data: Vaping Rate Among Women Aged 25–34 Reaches 18.3%, Compared With 14.4% for Men
The vaping rate among women aged 25 to 34 in Great Britain reached 18.3% in 2025, up from 13.7% in 2024 and 8.3% in 2020, according to data from the Office for National Statistics (ONS). The figure was the highest for this group since records began in 2014 and exceeded the 14.4% recorded among men of the same age. Adults aged 25 to 34 also overtook those aged 16 to 24 as the age group with the highest vaping prevalence. Overall, about 5.4 million adults in Great Britain used e-cigarettes in 2025, broadly unchanged from the previous year.
DATA
Oct.13
Imperial Brands Plans to Cut Nearly 18% of Workforce as German Plant Closure and Polish Outsourcing Drive Restructuring
Imperial Brands Plans to Cut Nearly 18% of Workforce as German Plant Closure and Polish Outsourcing Drive Restructuring
Imperial Brands disclosed on November 17, 2026, that its global manufacturing and organisational restructuring is expected to reduce between 4,200 and 4,600 roles by the end of 2030, equivalent to approximately 16%–18% of its workforce at the end of 2025. The first phase covers 2,100 roles with departures confirmed or subject to consultation, while a further 2,100–2,500 positions are expected to be eliminated by 2030. The company is proceeding with the closure of its Langenhagen factory in Germany, has sold its manufacturing facility in Taiwan, and has transferred selected finance, procurement and supply-chain operations in Poland to Capgemini. The restructuring programme is expected to cost approximately £740 million, with Imperial targeting at least £320 million in annual cost savings by 2030.
company
Nov.18
Product | KUMI SCENIC 50K Offers Nicotine and 6-Methyl Nicotine Versions as 6-MN Products Appear in Multiple U.S. State Directories, With Louisiana Listing FDA Exemption
Product | KUMI SCENIC 50K Offers Nicotine and 6-Methyl Nicotine Versions as 6-MN Products Appear in Multiple U.S. State Directories, With Louisiana Listing FDA Exemption
An October 2026 review of U.S. state vapor product directories found KUMI 6 SCENIC 50K listed in Louisiana and Nebraska. Louisiana classifies 20 related product entries as “FDA EXEMPTION.” The SCENIC platform is marketed in both conventional nicotine-salt and NoNic6 formulations, each advertised with 22mL e-liquid capacity and up to 50,000 puffs. U.S. wholesaler Midwest Goods listed both versions in August 2025 with a suggested retail price of $19.99 each. The NoNic6 version is associated with 6-methylnicotine and is also marketed by some distributors as “nicotine-free.”
product
Oct.27
Ukraine Raises Excise Stamp Fees for Tobacco, Heated Tobacco and Vape Liquids by 30.5% as Parliament Backs E-Excise Delay to 2027
Ukraine Raises Excise Stamp Fees for Tobacco, Heated Tobacco and Vape Liquids by 30.5% as Parliament Backs E-Excise Delay to 2027
Ukraine's Cabinet of Ministers adopted Resolution No. 1259 on October 15, 2026, increasing excise stamp production fees for tobacco products and e-cigarette liquids by approximately 30.5%, from UAH 0.1643 to UAH 0.2144 per stamp. Fees for alcoholic beverages rose by about 30.2%. Separately, Ukraine's parliament passed Bill No. 15532 on October 13, proposing to postpone the full implementation of electronic excise stamps and traceability for alcohol, tobacco and e-cigarette liquids from November 1, 2026, to July 1, 2027. Parliament cited additional testing, configuration and integration requirements. The bill was sent to the president for signature on October 19.
Regulations
Oct.21
India Duty-Free Nicotine Pouch Sales Face Regulatory Test as ZYN, FOX Classification Remains Open
India Duty-Free Nicotine Pouch Sales Face Regulatory Test as ZYN, FOX Classification Remains Open
The Bombay High Court has ruled that airport duty-free shops are not exempt from India's domestic regulatory laws merely because they operate beyond the customs barrier, leaving in place a sales halt covering ZYN and FOX nicotine pouches at Mumbai's international airport. The court, however, did not determine that the products necessarily qualify as "drugs" under India's Drugs and Cosmetics Act. The retailers have four weeks to submit product information to the appropriate authorities, including CDSCO, which must complete its review within 30 days of receiving the submissions.
Sep.24